Telus PeptidesAbaloparatide
Other FDA-approved drug
Parathyroid hormone-related peptide analog (PTHrP 1-34) · also known as Tymlos
For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.
Abaloparatide is a daily-administered bone-building agent that selectively activates the PTH1 receptor. The US product, Tymlos, is a multidose pen delivering 80 micrograms per dose, and the label does not recommend cumulative use beyond 2 years. The 3 mg vial in this entry is a research format, and its figures are arithmetic rather than a labeled presentation.
Commonly reported dosing (3 mg vial)
| Phase | Dose | Volume | U-100 units |
|---|---|---|---|
| Standard | 80 mcg | 0.08 mL | 8 |
Commonly reported reconstitution steps
- Vials are usually brought to room temperature (about 15-20 minutes) first.
- 3 mL of bacteriostatic water is added slowly down the inside wall of the 3 mg vial.
- The vial is swirled gently until clear, not shaken.
- This gives 1 mg/mL. Mixed vials are typically labeled with the date and refrigerated.
Storage
Before mixing: Storage of a lyophilized research vial is not defined by the approved-pen label; reference sources advise following the exact product instructions.
After mixing: No universal use-by period applies to a mixed research vial; product-specific stability information governs.
How it works
Selective activation of the PTH1 receptor in a transient pattern promotes bone formation, with a comparatively smaller resorptive effect than continuous PTH exposure.
Researched for
- The ACTIVE phase 3 trial of 80 mcg daily for 18 months in postmenopausal women reported fewer vertebral fractures than placebo.
- The ATOM trial studied men with osteoporosis and ACTIVE-J studied Japanese participants at high fracture risk.
- A dose-ranging trial compared 20, 40 and 80 mcg daily.
Notes
- Label-reported common reactions include hypercalciuria, dizziness, nausea, headache and palpitations; orthostatic hypotension is a labeled precaution.
- Absolute bioavailability after subcutaneous administration was 36% in the label's pharmacokinetic data.
- The approved pen is a 3120 mcg/1.56 mL solution, not a lyophilized 3 mg vial, so research-vial figures are not interchangeable with it.
- At 3 mL, a 3 mg vial gives 1 mg/mL; one U-100 unit is 10 mcg.
- Brand-name pens and kits are pre-measured; the reconstitution figures here apply to vials that require mixing.